SCHEMBL25972166

SCHEMBL25972166

CC(=O)c1nn(Cc2cc(F)cc(F)c2)c(Cl)c1C=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.38
P2RY14 Q15391 2/20 0.35
ALDH1A1 P00352 3/20 0.35
ENPP2 Q13822 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
GAA P10253 1/20 0.32
GRN P28799 1/20 0.32
SORT1 Q99523 1/20 0.32
RIPK1 Q13546 2/20 0.31
P2RX7 Q99572 1/20 0.31
AKR1B1 P15121 1/20 0.31
RORC P51449 1/20 0.31
LMNA P02545 1/20 0.31
MAPT P10636 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
HDAC3 O15379 1/20 0.31
HDAC4 P56524 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC7 Q8WUI4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25972285 0.88 GRIN1 (0.39) KDM4EALDH1A1P2RX7
SCHEMBL23070397 0.84 LMNA (0.41) KDM4EALDH1A1MEN1KMT2AGAA
SCHEMBL25972168 0.84 KDM4E (0.35) KDM4EP2RY14ALDH1A1ENPP2MEN1
SCHEMBL25972149 0.83 KMT2A (0.51) KDM4EALDH1A1MEN1KMT2AGRN
SCHEMBL25972169 0.82 P2RY14 (0.34) KDM4EP2RY14ALDH1A1ENPP2MEN1
SCHEMBL25972272 0.81 MEN1 (0.38) KDM4EMEN1KMT2ARIPK1RORC
SCHEMBL25972443 0.77 KMT2A (0.49) KDM4EMEN1KMT2ALMNAMAPT
SCHEMBL25972119 0.76 GAA (0.36) KDM4EALDH1A1MEN1KMT2AGAA
SCHEMBL28991093 0.75 KDM4E (0.37) KDM4EP2RY14ALDH1A1ENPP2MEN1
SCHEMBL28991089 0.75 KDM4E (0.37) KDM4EP2RY14ALDH1A1ENPP2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11718612-B2 Inhibitors of receptor interacting protein kinase I for the treatment of disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718612-B2 Inhibitors of receptor interacting protein kinase I for the treatment of disease RIPK1, RIPK2, RIPK4 KDM4E 3689/4885P2RY14 1888/4885ALDH1A1 4554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.